The TCW trial randomized 172 patients ≥70 years with severe aortic stenosis and complex coronary disease to FFR-guided PCI plus TAVI versus SAVR plus CABG. At 1 year the percutaneous strategy met non-inferiority and demonstrated superiority for a composite endpoint driven by lower mortality and life‑threatening bleeding.